Arabic Arabic English English French French German German
dark

Updated recommendations for managing hereditary breast cancer

(HealthDay)—One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, according to a rapid recommendation update published by the American Society for Clinical Oncology (ASCO). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Face masks may expose children to higher carbon dioxide levels

Next Post

Reading problems in childhood tied to poorer memory scores in adulthood

Related Posts
Total
0
Share